Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties.

Lippiello P, Letchworth SR, Gatto GJ, Traina VM, Bencherif M.

J Mol Neurosci. 2006;30(1-2):19-20.

PMID:
17192610
2.

Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors.

Bencherif M, Hauser TA, Jordan KG, Gatto GJ.

J Mol Neurosci. 2006;30(1-2):17-8.

PMID:
17192609
3.

Cognitive enhancement in man with ispronicline, a nicotinic partial agonist.

Dunbar GC, Kuchibhatla R.

J Mol Neurosci. 2006;30(1-2):169-72.

PMID:
17192668
4.

TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.

Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M.

CNS Drug Rev. 2004 Summer;10(2):147-66. Review.

5.

In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.

Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. doi: 10.1124/jpet.110.167213. Epub 2010 May 26.

6.

Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI).

Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J.

J Psychopharmacol. 2007 Mar;21(2):171-8. Erratum in: J Psychopharmacol. 2008 Aug;22(6):698.

PMID:
17329297
7.

Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.

Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rodefer JS.

Curr Opin Investig Drugs. 2008 Jan;9(1):47-56. Review.

PMID:
18183531
8.

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.

Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT, et al.

J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.

PMID:
7913497
9.

SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist.

Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, La Rosa S, Micco I, Pollastrini M, Quinn J, Roncarati R, Scali C, Valacchi M, Varrone M, Zanaletti R.

Bioorg Med Chem. 2009 Jul 15;17(14):5247-58. doi: 10.1016/j.bmc.2009.05.040. Epub 2009 May 21. Erratum in: Bioorg Med Chem. 2010 Jan 15;18(2):985.

PMID:
19515567
10.

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Levin ED, McClernon FJ, Rezvani AH.

Psychopharmacology (Berl). 2006 Mar;184(3-4):523-39. Epub 2005 Oct 12. Review.

PMID:
16220335
11.

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.

Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J, et al.

Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:50-61.

PMID:
8534424
12.

Nicotinic acetylcholine involvement in cognitive function in animals.

Levin ED, Simon BB.

Psychopharmacology (Berl). 1998 Aug;138(3-4):217-30. Review.

PMID:
9725745
13.

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.

Dunbar G, Boeijinga PH, Demazières A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R.

Psychopharmacology (Berl). 2007 May;191(4):919-29. Epub 2007 Jan 16.

PMID:
17225162
14.

Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.

Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD.

Curr Pharm Des. 2010 Jan;16(3):323-43. Review.

PMID:
20109142
15.

Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.

Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG.

Curr Pharm Des. 2010 Jan;16(3):309-22. Review.

PMID:
20109141
16.

Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.

Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A.

Alzheimer Dis Assoc Disord. 2001 Aug;15 Suppl 1:S19-25.

PMID:
11669505
17.

The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S.

Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):399-411. Review.

PMID:
12769612
19.

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Maelicke A.

Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:11-8. Review.

PMID:
10971047
20.

Central nicotinic receptors, neurotrophic factors and neuroprotection.

Belluardo N, Mudò G, Blum M, Fuxe K.

Behav Brain Res. 2000 Aug;113(1-2):21-34. Review.

PMID:
10942029

Supplemental Content

Support Center